phase iii trial of pf-07220060 and fulvestrant in hr /her2- breast cancer
Published 2 weeks ago • 31 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
2:31
pf-07220060 in hr her2- mbc who progressed on prior cdk4/6 inhibitors and endocrine therapy
-
3:41
pf-07220060, a novel oral cdk4-selective inhibitor, in hr /her2- mbc
-
1:41
postmonarch: abemaciclib with fulvestrant in pretreated hr /her2- breast cancer
-
1:49
phase ib data capitello-292: capivasertib palbociclib fulvestrant in hr /her2- breast cancer
-
2:17
design and results of phase iii falcon trial of fulvestrant for advanced breast cancer
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
0:53
postmonarche: abemaciclib fulvestrant in hr /her2- mbc following cdk4/6i & endocrine therapy
-
5:02
samuraciclib in combination with fulvestrant in patients with advanced hr /her2- breast cancer
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
1:22
dr. slamon the phase iii results of monaleesa-3 trial in hr /her2- breast cancer
-
1:11
unmet needs in the use of cdk4/6 inhibitors in early-stage hr /her2- breast cancer
-
4:06
serena-2: camizestrant vs fulvestrant in post-menopausal women with advanced er /her- breast cancer
-
1:18
the significance of fulvestrant for hormone receptor-positive advanced breast cancer
-
2:46
ameera-3: amcenestrant does not improve pfs in er /her2- breast cancer
-
5:28
capitello-291: capivasertib fulvestrant for ai-resistant hr /her2- advanced breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
2:45
paloma-3: phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer
-
1:21
qol in monaleesa-2, 3, and 7
-
1:00
therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancer